Present full clinical data from KURRENT-HN trial of tipifarnib with alpelisib in PIK3CA-m HNSCC
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 20 Oct 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Present full clinical data from KURRENT-HN trial of tipifarnib in combination with alpelisib in PIK3CA-m HNSCC 2H 2025”
What we found
Evidence strength B What the grades mean
Kura Oncology presented KURRENT-HN clinical data (tipifarnib + alpelisib in PIK3CA-altered HNSCC) as a poster at ESMO 2025 Congress on October 20, 2025, within the 2H 2025 target.
-
B Tipifarnib and Alpelisib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Full poster with data cutoff Aug 29, 2025, presented at ESMO 2025
-
B Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress Announces KURRENT-HN data presented at ESMO 2025, Oct 17-21, Berlin
-
B Kura Oncology Reports Third Quarter 2025 Financial Results Q3 2025 report confirms KURRENT-HN data presented at ESMO in October 2025
-
D Kura Oncology Sets Two FTI Program Events, ESMO Data Review Confirms KURRENT-HN poster scheduled for Oct 20, 2025 at ESMO
Checked 15 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-KURA-000238 · Corrections policy